



## Regorafenib (monohydrate)

**Catalog No: tcsc1205** 

Available Sizes
Size: 10mg
Size: 50mg
Size: 100mg
Size: 200mg
Size: 500mg
Size: 1g
Size: 2g
Size: 5g
Specifications
CAS No: 1019206-88-2
Formula: $\mathbf{C_{21}^{H}_{17}^{Clf}_{4}^{N_{4}O_{4}}}$
Pathway: Protein Tyrosine Kinase/RTK;MAPK/ERK Pathway;Protein Tyrosine Kinase/RTK;Autophagy
Target: VEGFR;Raf;PDGFR;Autophagy
Purity / Grade: >98%
Solubility





H20:

## **Alternative Names:**

BAY 73-4506 monohydrate

## **Observed Molecular Weight:**

500.83

## **Product Description**

Regorafenib monohydrate is a multi-target inhibitor for **VEGFR1/2/3**, **PDGFR\beta**, **Kit**, **RET** and **Raf-1** with **IC**<sub>50</sub>s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.

IC50 & Target: IC50: 13 nM (VEGFR1), 4.2 nM (VEGFR2), 46 nM (VEGFR3), 22 nM (PDGFRβ), 7 nM (Kit), 1.5 nM (RET), 2.5 nM (Raf-1)

In Vitro: Regorafenib potently inhibits VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells with an IC $_{50}$  of 3 nM. In HAoSMCs, regorafenib inhibits PDGFR-β autophosphorylation after stimulation with PDGF-BB, with an IC $_{50}$  of 90 nM. Regorafenib inhibits the proliferation of VEGF165-stimulated HUVECs, with an IC $_{50}$  of 3 nM $^{[1]}$ . Regorafenib causes a concentration-dependent decrease in Hep3B cell growth, having an IC $_{50}$  of 5 μM. Regorafenib subsequently increases the levels of phospho-c-Jun, a JNK target, but not total c-Jun in Hep3B cells $^{[3]}$ .

*In Vivo:* Regorafenib effectively inhibits growth of the Colo-205 xenografts in the dose range of 10-100 mg/kg reaching a TGI of 75% at day 14 at the 10 mg/kg dose. In the MDA-MB-231 model, regorafenib is highly efficacious at a dose as low as 3 mg/kg, resulting in a significant TGI of 81%, which increases to 93% at doses of 10 and 30 mg/kg, where tumor stasis is reached<sup>[1]</sup>.

$$\begin{array}{c} CI \\ F \\ H \end{array}$$

$$H_2O$$

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!